L6H21

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565158

CAS#: NONE

Description: L6H21 is an inhibitor of the interaction and signaling transduction of LPS-TLR4/MD-2 (myeloid differentiation 2).


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-03-29. Prices are subject to change without notice.

L6H21 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 565158
Name: L6H21
CAS#: NONE
Chemical Formula: C18H18O4
Exact Mass: 298.1205
Molecular Weight: 298.34
Elemental Analysis: C, 72.47; H, 6.08; O, 21.45


Synonym: L6H21

IUPAC/Chemical Name: (E)-2,3-dimethoxy-4'-methoxychalcone

InChi Key: IECVLMVZGCYCSZ-FMIVXFBMSA-N

InChi Code: InChI=1S/C18H18O4/c1-20-15-10-7-13(8-11-15)16(19)12-9-14-5-4-6-17(21-2)18(14)22-3/h4-12H,1-3H3/b12-9+

SMILES Code: O=C(C1=CC=C(OC)C=C1)/C=C/C2=CC=CC(OC)=C2OC


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Yu FZ, Wen X, Ding WL, Zhu JY, Du SH, Shen QF, Ni X, Wang J. L6H21 prolonged rats survival after limb allotransplantation by inhibiting acute rejection. Eur Rev Med Pharmacol Sci. 2017 Apr;21(8):1891-1903. PubMed PMID: 28485788.

2: Wang Y, Shan X, Chen G, Jiang L, Wang Z, Fang Q, Liu X, Wang J, Zhang Y, Wu W, Liang G. MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis. Br J Pharmacol. 2015 Sep;172(17):4391-405. doi: 10.1111/bph.13221. Epub 2015 Jul 21. PubMed PMID: 26076332; PubMed Central PMCID: PMC4556476.

3: Hong GL, Yang ZN, He YY, Tan JP, Liangm A, Zhao GJ, Lu ZQ. [Mono-carbonyl analogues of curcumin prevents paraquat-induced apoptosis in HK-2 cell line by inhibiting oxidative damage and inflammation]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2017 Sep 20;35(9):641-647. doi: 10.3760/cma.j.issn.1001-9391.2017.09.001. Chinese. PubMed PMID: 29294513.

4: Chen X, Yu W, Li W, Zhang H, Huang W, Wang J, Zhu W, Fang Q, Chen C, Li X, Liang G. An anti-inflammatory chalcone derivative prevents heart and kidney from hyperlipidemia-induced injuries by attenuating inflammation. Toxicol Appl Pharmacol. 2018 Jan 1;338:43-53. doi: 10.1016/j.taap.2017.11.003. Epub 2017 Nov 8. PubMed PMID: 29128402.

5: Zhang Y, Wu B, Zhang H, Ge X, Ying S, Hu M, Li W, Huang Y, Wang L, Chen C, Shan X, Liang G. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease. J Cell Mol Med. 2018 Feb;22(2):936-947. doi: 10.1111/jcmm.13395. Epub 2017 Oct 27. PubMed PMID: 29077272; PubMed Central PMCID: PMC5783870.

6: Fang Q, Wang J, Zhang Y, Wang L, Li W, Han J, Huang W, Liang G, Wang Y. Inhibition of myeloid differentiation factor-2 attenuates obesity-induced cardiomyopathy and fibrosis. Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):252-262. doi: 10.1016/j.bbadis.2017.09.026. Epub 2017 Sep 29. PubMed PMID: 28965884.

7: Fang Q, Wang L, Yang D, Chen X, Shan X, Zhang Y, Lum H, Wang J, Zhong P, Liang G, Wang Y. Blockade of myeloid differentiation protein 2 prevents obesity-induced inflammation and nephropathy. J Cell Mol Med. 2017 Dec;21(12):3776-3786. doi: 10.1111/jcmm.13287. Epub 2017 Aug 2. PubMed PMID: 28767204; PubMed Central PMCID: PMC5706499.

8: Xu Z, Li W, Han J, Zou C, Huang W, Yu W, Shan X, Lum H, Li X, Liang G. Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). Sci Rep. 2017 Mar 21;7:44911. doi: 10.1038/srep44911. PubMed PMID: 28322341; PubMed Central PMCID: PMC5359637.

9: Han J, Zou C, Mei L, Zhang Y, Qian Y, You S, Pan Y, Xu Z, Bai B, Huang W, Liang G. MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway. Basic Res Cardiol. 2017 Jan;112(1):9. doi: 10.1007/s00395-016-0599-5. Epub 2016 Dec 24. PubMed PMID: 28013347.

10: Fang Q, Zhao L, Wang Y, Zhang Y, Li Z, Pan Y, Kanchana K, Wang J, Tong C, Li D, Liang G. A novel chalcone derivative attenuates the diabetes-induced renal injury via inhibition of high glucose-mediated inflammatory response and macrophage infiltration. Toxicol Appl Pharmacol. 2015 Jan 15;282(2):129-38. doi: 10.1016/j.taap.2014.10.021. Epub 2014 Nov 8. PubMed PMID: 25447405.